The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly ...

Immunotherapy is reshaping treatment for pemphigus and bullous pemphigoid with promising results from biologics like rituximab and dupilumab. Learn how precision immunology is advancing care.

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

Cite this: Bullous Pemphigoid: A Short Review - Medscape - Nov 01, 2009. Abstract and Introduction; Clinical Manifestations; Diagnosis of Bullous Pemphigoid; Pathogenesis; Differential Diagnosis; ...

Porphyria cutanea tarda (PCT) is a metabolic disease of the heme synthesizing enzyme, uroporphyrinogen decarboxylase, which leads to a buildup of toxic heine precursors. Manifestations of porphyria ...